Betamethasone dipropionate and salicylic acid lotion for nonscalp dermatoses.
A multicentric open study was conducted to evaluate the efficacy and safety of betamethasone dipropionate and salicylic acid lotion in 86 patients with psoriasis or other steroid-responsive dermatoses of nonscalp body areas. Medication was applied to affected areas for 14 to 31 days. Patients were evaluated weekly. Within 14 to 21 days of therapy, there were favorable results in 68/86 (79%) patients. A complete clearing or marked improvement of signs and symptoms was achieved in 78/86 (91%) patients; improvement occurred in 7/86 (8%). Treatment failed in one (1%) patient. Three transient adverse reactions were reported.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004485:Eczema / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy; D012459:Salicylates / Q000008:administration & dosage*; D020156:Salicylic Acid; D012871:Skin Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D012459:Salicylates; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D020156:Salicylic Acid